ResearcherStiftung CharitéNo recent work listed

Lukas Ehlen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0820-6594; OpenAlex author ID A5057950625. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2020: 1 paper

Papers 1

Novel methods for in vitro modeling of pancreatic cancer reveal important aspects for successful primary cell culture. Co-author DOI 10.1186/s12885-020-06929-8 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Katharina Beyer · 1 shared paper, 2020 · strength 0.10
- Paper Novel methods for in vitro modeling of pancreatic cancer reveal important aspects for successful primary cell culture. DOI 10.1186/s12885-020-06929-8 ↗
Carsten Kamphues · 1 shared paper, 2020 · strength 0.10
- Paper Novel methods for in vitro modeling of pancreatic cancer reveal important aspects for successful primary cell culture. DOI 10.1186/s12885-020-06929-8 ↗
Frederick Klauschen · 1 shared paper, 2020 · strength 0.10
- Paper Novel methods for in vitro modeling of pancreatic cancer reveal important aspects for successful primary cell culture. DOI 10.1186/s12885-020-06929-8 ↗
Florian Nino Loch · 1 shared paper, 2020 · strength 0.10
- Paper Novel methods for in vitro modeling of pancreatic cancer reveal important aspects for successful primary cell culture. DOI 10.1186/s12885-020-06929-8 ↗
Georgios Antonios Margonis · 1 shared paper, 2020 · strength 0.10
- Paper Novel methods for in vitro modeling of pancreatic cancer reveal important aspects for successful primary cell culture. DOI 10.1186/s12885-020-06929-8 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.